Drug intelligence / Profile preview

7,9-di-tert-butyl-oxaspiro[4.5]deca-6,9-diene-2,8-dione

Development stage: Preclinical
Lead developer: University of Johannesburg
Modality: Small Molecules

Overview

7,9-di-tert-butyl-oxaspiro[4.5]deca-6,9-diene-2,8-dione is a small molecule compound isolated from the methanolic extract of *Carpobrotus edulis* (commonly known as sour fig). It is currently being investigated for its potential anticancer properties, specifically against pancreatic cancer. Research presented at AACR 2026 indicates that the compound induces apoptosis in MIA PaCa2 pancreatic cancer cells by activating the extrinsic TNF-mediated apoptotic pathway. Mechanistic studies, including protein-ligand docking, suggest that the compound has a high binding affinity for several key apoptotic and signaling proteins, including the Tumor Necrosis Factor Receptor (TNFR), Fas-associated protein with death domain (FADD), p53, Bak1, and Signal Transducer and Activator of Transcription 3 (STAT3). Preclinical assays have demonstrated that the compound selectively targets cancer cells while sparing non-cancerous MRC-5 cells, suggesting a favorable safety profile for further development.

Other names: 7,9-Ditert-butyl-oxaspiro [4.5] deca-6,9-diene-2,8-dione

Targets

BAKTNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TP53 (Cellular Tumor Antigen p53 R175H)STAT3 (Signal Transducer and Activator of Transcription 3)FADD (Fas-associated protein with death domain)

Beyond the preview

Go deeper on 7,9-di-tert-butyl-oxaspiro[4.5]deca-6,9-diene-2,8-dione.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 7,9-di-tert-butyl-oxaspiro[4.5]deca-6,9-diene-2,8-dione.

Explore the full profile